Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more
Theratechnologies Inc. (THTX) - Total Assets
Latest total assets as of May 2025: $51.27 Million USD
Based on the latest financial reports, Theratechnologies Inc. (THTX) holds total assets worth $51.27 Million USD as of May 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Theratechnologies Inc. - Total Assets Trend (1996–2024)
This chart illustrates how Theratechnologies Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Theratechnologies Inc. - Asset Composition Analysis
Current Asset Composition (November 2024)
Theratechnologies Inc.'s total assets of $51.27 Million consist of 82.5% current assets and 17.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.1% |
| Accounts Receivable | $15.60 Million | 29.3% |
| Inventory | $5.28 Million | 9.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.57 Million | 14.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Theratechnologies Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theratechnologies Inc.'s current assets represent 82.5% of total assets in 2024, an increase from 81.7% in 1996.
- Cash Position: Cash and equivalents constituted 11.1% of total assets in 2024, down from 46.6% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 29.3% of total assets.
Theratechnologies Inc. Competitors by Total Assets
Key competitors of Theratechnologies Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Theratechnologies Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Theratechnologies Inc. generates 1.61x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Theratechnologies Inc. is currently not profitable relative to its asset base.
Theratechnologies Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.84 | 1.10 | 1.90 |
| Quick Ratio | 0.65 | 1.00 | 1.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.15 Million | $ 5.34 Million | $ 30.29 Million |
Theratechnologies Inc. - Advanced Valuation Insights
This section examines the relationship between Theratechnologies Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.13 |
| Latest Market Cap to Assets Ratio | 2.43 |
| Asset Growth Rate (YoY) | -31.4% |
| Total Assets | $53.34 Million |
| Market Capitalization | $129.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Theratechnologies Inc.'s assets at a significant premium ( 2.43x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Theratechnologies Inc.'s assets decreased by 31.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Theratechnologies Inc. (1996–2024)
The table below shows the annual total assets of Theratechnologies Inc. from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-11-30 | $53.34 Million | -31.41% |
| 2023-11-30 | $77.77 Million | -16.61% |
| 2022-11-30 | $93.26 Million | -21.77% |
| 2021-11-30 | $119.21 Million | +19.04% |
| 2020-11-30 | $100.14 Million | -14.81% |
| 2019-11-30 | $117.56 Million | +5.77% |
| 2018-11-30 | $111.14 Million | +87.47% |
| 2017-11-30 | $59.29 Million | +50.36% |
| 2016-11-30 | $39.43 Million | +5.27% |
| 2015-11-30 | $37.46 Million | +31.39% |
| 2014-11-30 | $28.51 Million | +21.82% |
| 2013-11-30 | $23.40 Million | -36.02% |
| 2012-11-30 | $36.58 Million | -28.57% |
| 2011-11-30 | $51.20 Million | -27.14% |
| 2010-11-30 | $70.28 Million | +6.98% |
| 2009-11-30 | $65.70 Million | +50.69% |
| 2008-11-30 | $43.60 Million | -41.52% |
| 2007-11-30 | $74.55 Million | +66.97% |
| 2006-11-30 | $44.65 Million | -2.79% |
| 2005-11-30 | $45.93 Million | -19.74% |
| 2004-11-30 | $57.23 Million | -21.47% |
| 2003-11-30 | $72.88 Million | -18.83% |
| 2002-11-30 | $89.78 Million | -0.66% |
| 2001-11-30 | $90.38 Million | +64.34% |
| 2000-11-30 | $54.99 Million | +198.81% |
| 1999-11-30 | $18.40 Million | +48.00% |
| 1998-11-30 | $12.43 Million | +46.24% |
| 1997-11-30 | $8.50 Million | -47.68% |
| 1996-11-30 | $16.25 Million | -- |